Jaguar Health Provides Updates Regarding Commercial, Educational & Product Development Programs and 2017 Results for Mytesi Since Merger (August–December 2017)

Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis, today provided the following updates regarding commercial, educational and product development programs and 2017 results.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122006522/en/

(Graphic: Business Wire)

Mytesi^® Sales Update (August 2017 – December of 2017)

Effective July 31, 2017, Jaguar merged with Napo Pharmaceuticals, Inc. (Napo) and acquired its first-in-class, FDA-approved anti-secretory human prescription drug product, Mytesi^® (crofelemer). For the period August 1, 2017 through December 31, 2017, preliminary sales of Mytesi^® were approximately $1.40 million. During the aforementioned period, Mytesi^® sales increased more than 78% relative to average monthly Mytesi^® sales that took place from January through July of 2017, which is before marketing efforts were deployed in the combined Company and the deployment in the fourth quarter of Napo’s team of nine dedicated sales reps. On average during the August 1, 2017 through December 31, 2017 period, sales increased 17.71% each month over the prior month.

Six of Napo’s nine highly trained Mytesi^® sales representatives are former long-term employees of the HIV portfolio business of drugmaker Bristol-Myers Squibb, while the remainder of the team possess extensive experience in drug sales to both HIV healthcare providers and gastroenterologists.

“Napo has identified a total high-potential prescriber base of 3,500 high-volume ART prescribers (HIV specialists) and 1,500 gastroenterologists who see the highest number of people living with HIV. The Napo sales force is located in the U.S. geographies with the highest potential, and is targeting the prescribers with the highest potential to drive Mytesi^® business. From September 1, 2017 through November 30, 2017, there was an increase of 86% in new Mytesi^® prescribers among gastroenterologists and 8% in HIV specialists, coincident with the deployment of our direct sales force,” Lisa Conte, Jaguar's President and CEO, stated. “According to data provided by IQVIA, the number of Mytesi^® prescriptions written by physicians increased an average of 9.5% each month over the prior month during the August 1, 2017 through December 31, 2017 period. Additionally, patient redemptions of our Mytesi^® Copay Savings Card increased an average of 7% each month over the prior month during the same period.”